Cappelli Andrea, Pericot Mohr Gal la, Giuliani Germano, Galeazzi Simone, Anzini Maurizio, Mennuni Laura, Ferrari Flora, Makovec Francesco, Kleinrath Eva M, Langer Thierry, Valoti Massimo, Giorgi Gianluca, Vomero Salvatore
Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università di Siena, Via A. Moro, 53100 Siena, Italy.
J Med Chem. 2006 Nov 2;49(22):6451-64. doi: 10.1021/jm0603163.
The 4-phenylquinoline fragment of novel AT(1) receptor antagonists 4 based on imidazo[4,5-b]pyridine moiety was replaced by 4-phenylisoquinolinone (compounds 5) or 1-phenylindene (compounds 6) scaffolds to investigate the structure-activity relationships. Binding studies showed that most of the synthesized compounds display high affinity for the AT(1) receptor. Because of the in vitro high potency of carboxylic acids 5b,f, they were evaluated in permeability (in Caco-2 cells) and in pharmacokinetic studies in comparison with quinoline derivatives 4b,i,j,k. The studies showed that these compounds are characterized by rapid excretion, low membrane permeability, and low oral bioavailability. The structure optimization of the indene derivatives led to compounds 6e,f possessing interesting AT(1) receptor affinities. Optimization produced polymerizing AT(1) receptor ligand 6c, which forms a thermoreversible polymer (poly-6c) and is released from the latter by a temperature-dependent kinetics. The results suggest the possibility of developing novel polymeric prodrugs based on a new release mechanism. Finally, a set of 34 AT(1) receptor antagonists was used as a new test for the evaluation of the predictive capability of the previously published qualitative and quantitative pharmacophore models.
基于咪唑并[4,5 - b]吡啶部分的新型AT(1)受体拮抗剂4的4 - 苯基喹啉片段被4 - 苯基异喹啉酮(化合物5)或1 - 苯基茚(化合物6)骨架取代,以研究构效关系。结合研究表明,大多数合成化合物对AT(1)受体具有高亲和力。由于羧酸5b,f在体外具有高效力,与喹啉衍生物4b,i,j,k相比,对它们进行了渗透性(在Caco - 2细胞中)和药代动力学研究。研究表明,这些化合物的特点是排泄迅速、膜通透性低和口服生物利用度低。茚衍生物的结构优化产生了具有有趣的AT(1)受体亲和力的化合物6e,f。优化产生了聚合性的AT(1)受体配体6c,它形成一种热可逆聚合物(聚 - 6c),并通过温度依赖性动力学从后者中释放出来。结果表明基于新释放机制开发新型聚合物前药的可能性。最后,使用一组34种AT(1)受体拮抗剂作为新的测试,以评估先前发表的定性和定量药效团模型的预测能力。